NCT06295484 Effect of Nasal CPAP Versus NIPPV On Diaphragm Electrical Activity (Edi) In VLBW Preterm Infants
| NCT ID | NCT06295484 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Sunnybrook Health Sciences Centre |
| Condition | Preterm Birth |
| Study Type | INTERVENTIONAL |
| Enrollment | 24 participants |
| Start Date | 2021-08-21 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 24 participants in total. It began in 2021-08-21 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Background: In premature babies, many organ systems are not fully grown and developed, including the lungs and respiratory muscles, so they will need breathing support to help them to breathe by preventing their tiny air sacs to collapse. This support commonly done by CPAP and Non-Invasive Positive Pressure Ventilation (NIPPV) therapy by giving some pressure and oxygen to their lungs through an interface placed on their noses. Both (CPAP and NIPPV) can be used as a support modality for respiratory distress syndrome, apnea of prematurity, and providing breathing support after extubation from the full mechanical breathing support. The CPAP supports the baby's immature lungs by delivering constant pressure to keep their lungs and breathing well supported. Whereas the NIPPV will use constant pressure in the background (similar to CPAP), and on top, it will give extra intermittent puffs at regular intervals to support the baby's breathing. The NIPPV is the most common choice by the clinicians when the traditional CPAP is no longer effective, to avoid the full mechanical breathing support and to protect the developing lungs. Studies suggested that NIPPV is better than the traditional CPAP in reducing the need of the baby to need full mechanical breathing support. This might be because the investigators tend to use lower pressures with CPAP (5-8 cmH2O) compared to relatively higher pressures with NIPPV. More recently, clinicians showed the safety of using equivalent higher CPAP pressures (\>9 cmH2O) to what the investigators use in the NIPPV in preterm babies. One way to measure the support that the investigators are giving to the patient with the different devices is to measure the diaphragm activity, which the investigators call the Edi signal, using a special feeding catheter and a specific machine to measure it. The catheter is placed and used as a routine feeding tube but has sensors at the end to measure this Edi signal. One opening of the tube will be connected to a computer to record the Edi signals. The other opening of the tube will be used for feeding.
Eligibility Criteria
Inclusion Criteria: * Clinically stable preterm infants (defined as cardiovascular stability with normal blood pressure and heart rate for gestational age and no recent increase in apneic episodes or spells and confirmed by the attending neonatologist) * Birth weight less than 1500 grams * Admitted to the NICU at Sunnybrook Health Sciences Centre on nasal CPAP of 5 to 8 cmH2O support, for at least 48 hours and requiring less than 35% of oxygen Exclusion Criteria: * Congenital anomalies of the gastrointestinal tract * Phrenic nerve damage * Diaphragmatic paralysis * Esophageal perforation * Congenital or acquired neurological deficit (including significant intraventricular hemorrhage greater than Grade II) or neonatal seizure * Significant congenital heart disease (including symptomatic PDA) * Congenital anomalies of the diaphragm * Congenital anomalies of the respiratory tracts (e.g., Congenital Cystic Adenomatoid Malformation 'CCAM') * Ongoing treatment for sepsis * Ongoing treatment for necrotizing enterocolitis (NEC) * Ongoing treatment for lung infections * Narcotic analgesics * Gastric motility agents * Infants on nasal CPAP and requiring more than 35% oxygen * Infants with significant gastric residuals and vomiting * Infants with facial anomalies * Infants with pneumothorax or pneumomediastinum * Infants in the immediate postoperative period
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06295484 clinical trial?
This trial is open to participants of all sexes, aged 1 Day or older, up to 8 Months, studying Preterm Birth. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06295484 currently recruiting?
Yes, NCT06295484 is actively recruiting participants. Contact the research team at maher.shahroor@sunnybrook.ca for enrollment information.
Where is the NCT06295484 trial being conducted?
This trial is being conducted at Toronto, Canada.
Who is sponsoring the NCT06295484 clinical trial?
NCT06295484 is sponsored by Sunnybrook Health Sciences Centre. The trial plans to enroll 24 participants.